Realcan Pharmaceutical Group Co., Ltd. Share Price

Equities

002589

CNE1000013X5

Pharmaceuticals

End-of-day quote Shenzhen S.E. 23:00:00 25/04/2024 BST 5-day change 1st Jan Change
2.52 CNY 0.00% Intraday chart for Realcan Pharmaceutical Group Co., Ltd. +2.86% -22.94%

Financials

Sales 2021 21.06B 2.91B 233B Sales 2022 12.31B 1.7B 136B Capitalization 6.17B 851M 68.14B
Net income 2021 131M 18.08M 1.45B Net income 2022 -1.83B -253M -20.25B EV / Sales 2021 0.28 x
Net cash position 2021 34.82M 4.81M 385M Net cash position 2022 1.34B 184M 14.77B EV / Sales 2022 0.39 x
P/E ratio 2021
43.7 x
P/E ratio 2022
-3.32 x
Employees 5,118
Yield 2021
0.23%
Yield 2022
-
Free-Float 60.54%
More Fundamentals * Assessed data
Dynamic Chart
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2023 CI
Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) added to S&P Global BMI Index CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2023 CI
Realcan Pharmaceutical Group Co., Ltd. Approves the Executive Appointments CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2023 CI
Shanghai Pharmaceutical Co., Ltd. entered into an agreement to acquire 51% stake in Hunan Runji Pharmaceutical Co., Ltd. from Realcan Pharmaceutical Group Co., Ltd. for CNY 149 million CI
Realcan Pharmaceutical Group Co., Ltd. agreed to acquire 9.6409% of Shandong Lekang Jinyue Industrial Co., Ltd. from Yantai Chenghou Investment Co., Ltd for CNY 84.84 million. CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Nine Months Ended September 30, 2022 CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the Half Year Ended June 30, 2022 CI
Realcan Pharmaceutical Group Co., Ltd. Announces 2021 Final Profit Distribution Plan to Be Implemented (A Shares), Payable on July 22, 2022 CI
Realcan Pharmaceutical Group Co., Ltd.(XSEC:002589) dropped from S&P Global BMI Index CI
Realcan Pharmaceutical Group Co., Ltd. Approves Cash Dividend for the Year 2021 CI
Realcan Pharmaceutical Group Co., Ltd. Announces Profit Distribution Proposal for 2021 CI
Realcan Pharmaceutical Group Co., Ltd. Reports Earnings Results for the First Quarter Ended March 31, 2022 CI
Realcan Pharmaceutical Group Co., Ltd. agreed to acquire a 38.39992% stake in Tianjin Guohui Big Health Technology Co., Ltd. from Yantai Huishuo Enterprise Management Partnership Enterprise for approximately CNY 230 million. CI
More news
1 week+2.86%
Current month-16.83%
1 month-9.03%
3 months-14.58%
6 months-24.78%
Current year-22.94%
More quotes
1 week
2.37
Extreme 2.37
2.54
1 month
2.37
Extreme 2.37
3.17
Current year
2.05
Extreme 2.05
3.34
1 year
2.05
Extreme 2.05
3.96
3 years
2.05
Extreme 2.05
6.73
5 years
2.05
Extreme 2.05
9.27
10 years
2.05
Extreme 2.05
24.15
More quotes
Managers TitleAgeSince
Founder 58 20/11/09
Director of Finance/CFO 54 25/04/21
Chairman 59 20/11/09
Members of the board TitleAgeSince
Founder 58 20/11/09
Chairman 59 20/11/09
Director/Board Member 41 20/11/09
More insiders
Date Price Change Volume
26/04/24 2.52 0.00% 18,752,090
25/04/24 2.52 +2.02% 15,770,090
24/04/24 2.47 +0.82% 14,492,980
23/04/24 2.45 +2.08% 15,789,160
22/04/24 2.4 -2.04% 19,053,430

End-of-day quote Shenzhen S.E., April 25, 2024

More quotes
Realcan Pharmaceutical Group Co., Ltd., formerly REALCAN PHARMACEUTICAL CO., LTD., is a China-based medical service provider. The Company operates its businesses through three segments. The Medical segment is engaged in the provision of Chinese medicine materials, Chinese medicine tablets, Chinese patent medicines, chemical drug materials, chemical preparations, antibiotics, biochemical pharmaceuticals, biological products, psychotropic substances, anesthetic medicines and peptide hormones. The Equipment is engaged in the provision of medical equipment. The Mobile Medical segment is engaged in the provision of medical and logistics services and mobile medical information services. The Company conducts its businesses mainly within domestic markets, with Shandong as its main market.
Calendar
More about the company

Annual profits - Rate of surprise

  1. Stock Market
  2. Equities
  3. 002589 Stock